Coverage dated October 10, 2021 to October 13, 2021
FDA unlikely to rule on Merck's COVID pill before December
Headline from Omaha World-Herald, on the newest of 3 developments
WASHINGTON (AP) — The Food and Drug Administration said Thursday it will ask its outside experts to meet in late November to scrutinize Merck's pill to treat COVID-19.
Omaha World-Herald's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Developments in this update
3 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.
Merck asks FDA to authorize promising anti-COVID pill
Headline from KING 5 Seattle ·
Pharmaceutical companies seek FDA approval for the first ever COVID-19 pill
Headline from News West 9 ·
Newest
FDA unlikely to rule on Merck's COVID pill before December
If cleared by the Food and Drug Administration - a decision that could come in a matter of weeks - it would be the first pill shown to treat COVID-19. All other FDA-backed treatments against the disease require an IV or injection.
Merck is asking for the FDA to approve their anti-viral pill, Molnupiravir, that can reduce the risk of hospitalization or death in patients with COVID by 50%.
WASHINGTON (AP) — The Food and Drug Administration said Thursday it will ask its outside experts to meet in late November to scrutinize Merck's pill to treat COVID-19.
The Food and Drug Administration (FDA) scheduled a meeting for late next month for its advisory panel to discuss Merck’s antiviral pill designed to treat mild-to-moderate COVID-19.
